These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 6315516)

  • 21. Purification, crystallization and preliminary X-ray diffraction studies of alpha-toxin of Clostridium perfringens.
    Basak AK; Stuart DI; Nikura T; Bishop DH; Kelly DC; Fearn A; Titball RW
    J Mol Biol; 1994 Dec; 244(5):648-50. PubMed ID: 7990145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neonatal diarrhoea in pigs: alpha- and beta2-toxin produced by Clostridium perfringens].
    Hendriksen SW; van Leengoed LA; Roest HI; van Nes A
    Tijdschr Diergeneeskd; 2006 Dec; 131(24):910-3. PubMed ID: 17278609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purification and properties of a phospholipase C that has high activity toward sphingomyelin from Aspergillus saitoi.
    Matsuoka S; Kimura H; Kiuchi A; Ohkawa H; Yagi K
    Biotechnol Appl Biochem; 1987 Oct; 9(5):401-9. PubMed ID: 3675875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteolysis of Clostridium perfringens type A enterotoxin during purification.
    Park KB; Labbé RG
    Infect Immun; 1990 Jun; 58(6):1999-2001. PubMed ID: 2111289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further studies on complementation between mutants of Clostridium perfringens.
    Tatsuki T; Imagawa T; Kitajima H; Higashi Y; Chazono M; Yanagase Y; Amano T
    Biken J; 1981 Jun; 24(1-2):1-11. PubMed ID: 6272687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of toxic enzymes of Clostridium perfringens BP6K on technologically important media including a medium with Tween 80.
    Lettl A
    J Hyg Epidemiol Microbiol Immunol; 1978; 22(2):243-8. PubMed ID: 217931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of the ELISA test for detection of toxins of Clostridium perfringens type A].
    Nowakowska M; Matras J; Bartoszcze M
    Med Dosw Mikrobiol; 1988; 40(3):149-54. PubMed ID: 2907767
    [No Abstract]   [Full Text] [Related]  

  • 28. [Use of molasses and whey in culture media for the development and production of a toxin from Clostridium perfringens type D].
    Silva HJ; Giulietti AM; Segovia RF; Ertola RJ
    Rev Argent Microbiol; 1982; 14(2):85-90. PubMed ID: 6101000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The enteric toxins of Clostridium perfringens.
    Smedley JG; Fisher DJ; Sayeed S; Chakrabarti G; McClane BA
    Rev Physiol Biochem Pharmacol; 2004; 152():183-204. PubMed ID: 15517462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virulence factors of Clostridium perfringens.
    Smith LD
    Rev Infect Dis; 1979; 1(2):254-62. PubMed ID: 232935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Isolation of the theta-hemolysin of Cl. perfringens].
    Dolgikh MS; Blagoveshchenskiĭ VA; Sergeeva TI; Novoselova GN
    Vopr Med Khim; 1981; 27(1):129-32. PubMed ID: 6258318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purification of alpha toxin from Clostridium perfringens: phospholipase C.
    Jolivet-Reynaud C; Moreau H; Alouf JE
    Methods Enzymol; 1988; 165():91-4. PubMed ID: 2906730
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of protease on the production of Clostridium perfringens alpha toxin.
    Sato H; Yamakawa Y; Ito A; Murata R
    Jpn J Med Sci Biol; 1977 Feb; 30(1):44-6. PubMed ID: 195109
    [No Abstract]   [Full Text] [Related]  

  • 34. [Isolation of a purified theta-hemolysin from C1. perfingens type A and its use for titrating toxins and sera].
    Efimova MG
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):40-3. PubMed ID: 6295033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purification and some properties of Clostridium sporogenes hemorrhagic toxin.
    Hara-Kudo Y; Yamakawa Y; Kumagai S
    Biochem Biophys Res Commun; 1996 Oct; 227(2):413-8. PubMed ID: 8878529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification and characterization of Clostridium perfringens delta-toxin.
    Alouf JE; Jolivet-Reynaud C
    Infect Immun; 1981 Feb; 31(2):536-46. PubMed ID: 6260669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Clostridium perfringens phospholipase C in the pathogenesis of gas gangrene.
    Flores-Díaz M; Alape-Girón A
    Toxicon; 2003 Dec; 42(8):979-86. PubMed ID: 15019495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of residues in the carboxy-terminal domain of Clostridium perfringens alpha-toxin (phospholipase C) which are required for its biological activities.
    Walker N; Holley J; Naylor CE; Flores-Díaz M; Alape-Girón A; Carter G; Carr FJ; Thelestam M; Keyte M; Moss DS; Basak AK; Miller J; Titball RW
    Arch Biochem Biophys; 2000 Dec; 384(1):24-30. PubMed ID: 11147832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth conditions of clostridium perfringens type B for production of toxins used to obtain veterinary vaccines.
    Viana Brandi I; Domenici Mozzer O; Jorge EV; Vieira Passos FJ; Lopes Passos FM; Cangussu AS; Macedo Sobrinho E
    Bioprocess Biosyst Eng; 2014 Sep; 37(9):1737-42. PubMed ID: 24573216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of extracellular toxin production in Clostridium perfringens.
    Rood JI; Lyristis M
    Trends Microbiol; 1995 May; 3(5):192-6. PubMed ID: 7627457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.